VistaGen Therapeutics (NASDAQ:VTGN) Announces Earnings Results

VistaGen Therapeutics (NASDAQ:VTGN) posted its quarterly earnings data on Thursday. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.02), FiscalAI reports. The business had revenue of $0.26 million for the quarter, compared to analysts’ expectations of $0.16 million.

VistaGen Therapeutics Stock Performance

Shares of VistaGen Therapeutics stock traded down $0.27 on Thursday, hitting $3.80. The stock had a trading volume of 330,021 shares, compared to its average volume of 322,925. VistaGen Therapeutics has a twelve month low of $1.90 and a twelve month high of $4.65. The firm has a market capitalization of $116.58 million, a P/E ratio of -2.13 and a beta of 0.56. The stock has a 50 day moving average of $3.76 and a 200 day moving average of $2.98.

Institutional Investors Weigh In On VistaGen Therapeutics

A number of hedge funds have recently added to or reduced their stakes in VTGN. Cubist Systematic Strategies LLC acquired a new position in shares of VistaGen Therapeutics during the first quarter valued at about $25,000. Bank of America Corp DE grew its position in VistaGen Therapeutics by 1,068.0% during the fourth quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock valued at $62,000 after buying an additional 19,331 shares during the period. Marshall Wace LLP purchased a new position in VistaGen Therapeutics in the second quarter valued at about $69,000. Jane Street Group LLC bought a new position in shares of VistaGen Therapeutics during the 2nd quarter valued at approximately $190,000. Finally, Dimensional Fund Advisors LP increased its stake in shares of VistaGen Therapeutics by 56.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 68,017 shares of the company’s stock worth $241,000 after purchasing an additional 24,655 shares during the last quarter. 78.39% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

VTGN has been the topic of several research analyst reports. William Blair reaffirmed an “outperform” rating on shares of VistaGen Therapeutics in a research report on Tuesday, October 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of VistaGen Therapeutics in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised VistaGen Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold”.

VistaGen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.